4SC AG IPO-Jahr
Was ist das IPO-Jahr von 4SC AG?
IPO-Jahr von 4SC AG ist 2005
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit ipo-jahr ähnlich 4SC AG
- Rurelec PLC hat IPO-Jahr von 2004
- Kona Bay Technologies hat IPO-Jahr von 2004
- FE Investments hat IPO-Jahr von 2004
- JBF Industries hat IPO-Jahr von 2004
- Indiabulls Ventures hat IPO-Jahr von 2004
- Alexion Pharmaceuticals hat IPO-Jahr von 2004
- 4SC AG hat IPO-Jahr von 2005
- Compass Diversified hat IPO-Jahr von 2006
- Green Plains Inc hat IPO-Jahr von 2006
- Catalyst Pharmaceuticals Inc hat IPO-Jahr von 2006
- Greatland Gold Plc hat IPO-Jahr von 2006
- Capital Environment hat IPO-Jahr von 2006
- Athena Resources hat IPO-Jahr von 2006